Trial Profile
A Prospective, Open-label, Multicenter Observational Study to Evaluate the QoL of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jul 2013
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Janssen
- 20 Dec 2012 Actual initiation date changed from Oct 2009 to Nov 2009 as reported by ClinicalTrials.gov.
- 12 Jan 2012 Actual patient number is 60 according to ClinicalTrials.gov.
- 12 Jan 2012 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.